Products - Ear, nose and throat conditions | Topic

Showing 16 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 March 2025
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 May 2024
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2022
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 August 2021
Published:
26 March 2008
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 September 2020
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2019
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
6 August 2025
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for previously treated severe nasal polyps [ID1659]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Ear, nose and throat conditions Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 16 products

12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)

Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)

Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)

Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

Cochlear implants for children and adults with severe to profound deafness (TA566)

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]

STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

Benralizumab for previously treated severe nasal polyps [ID1659]

Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [TSID11918]

Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]

Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

Ear, nose and throat conditions Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 16 products

Guidance programme
1 selected